Literature DB >> 22682551

Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia.

Yalda Jamshidi1, Ilja M Nolte, Chrysoula Dalageorgou, Dongling Zheng, Toby Johnson, Rachel Bastiaenen, Suzanne Ruddy, Daniel Talbott, Kris J Norris, Harold Snieder, Alfred L George, Vanessa Marshall, Saad Shakir, Prince J Kannankeril, Patricia B Munroe, A John Camm, Steve Jeffery, Dan M Roden, Elijah R Behr.   

Abstract

OBJECTIVES: This study sought to determine whether variations in NOS1AP affect drug-induced long QT syndrome (LQTS).
BACKGROUND: Use of antiarrhythmic drugs is limited by the high incidence of serious adverse events including QT prolongation and torsades de pointes. NOS1AP gene variants play a role in modulating QT intervals in healthy subjects and severity of presentation in LQTS.
METHODS: This study carried out an association study using 167 single nucleotide polymorphisms (SNP) spanning the NOS1AP gene in 58 Caucasian patients experiencing drug-induced LQTS (dLQTS) and 87 Caucasian controls from the DARE (Drug-Induced Arrhythmia Risk Evaluation) study.
RESULTS: The rs10800397 SNP was significantly associated with dLQTS (odds ratio [OR]: 3.3, 99.95% confidence interval [CI]: 1.0 to 10.8, p = 3.7 × 10(-4)). The associations were more pronounced in the subgroup of amiodarone users, in which 3 SNPs, including rs10800397, were significantly associated (most significant SNP: rs10919035: OR: 5.5, 99.95% CI: 1.1 to 27.9, p = 3.0 × 10(-4)). We genotyped rs10919035 in an independent replication cohort of 28 amiodarone dLQTS cases versus 173 control subjects (meta-analysis of both studies: OR: 2.81, 99.95% CI: 1.62 to 4.89, p = 2.4 × 10(-4)). Analysis of corrected QT interval among 74 control subjects from our dataset showed a similar pattern of significance over the gene region as the case-control analysis. This pattern was confirmed in 1,480 control subjects from the BRIGHT (British Genetics of Hypertension Study) cohort (top SNP from DARE: rs12734991 in meta-analysis: increase in corrected QT interval per C allele: 9.1 ± 3.2 ms, p = 1.7 × 10(-4)).
CONCLUSIONS: These results provide the first demonstration that common variations in the NOS1AP gene are associated with a significant increase in the risk of dLQTS. This study suggests that common variations in the NOS1AP gene may have relevance for future pharmacogenomic applications in clinical practice permitting safer prescription of drugs for vulnerable patients.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22682551      PMCID: PMC3753216          DOI: 10.1016/j.jacc.2012.03.031

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  40 in total

Review 1.  Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions.

Authors:  S Nattel; B N Singh
Journal:  Am J Cardiol       Date:  1999-11-04       Impact factor: 2.778

2.  A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other.

Authors:  Dale R Nyholt
Journal:  Am J Hum Genet       Date:  2004-03-02       Impact factor: 11.025

Review 3.  Drug-induced prolongation of the QT interval.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

4.  Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms.

Authors:  Lili A Barouch; Robert W Harrison; Michel W Skaf; Gisele O Rosas; Thomas P Cappola; Zoulficar A Kobeissi; Ion A Hobai; Christopher A Lemmon; Arthur L Burnett; Brian O'Rourke; E Rene Rodriguez; Paul L Huang; João A C Lima; Dan E Berkowitz; Joshua M Hare
Journal:  Nature       Date:  2002-03-21       Impact factor: 49.962

5.  Rhythm control agents and adverse events in patients with atrial fibrillation.

Authors:  C J Taylor; J Hodgkinson; F D R Hobbs
Journal:  Int J Clin Pract       Date:  2010-05-12       Impact factor: 2.503

6.  Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers.

Authors:  Prince J Kannankeril; Kris J Norris; Shannon Carter; Dan M Roden
Journal:  Heart Rhythm       Date:  2011-03-21       Impact factor: 6.343

7.  Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism.

Authors:  Igor Splawski; Katherine W Timothy; Leah M Sharpe; Niels Decher; Pradeep Kumar; Raffaella Bloise; Carlo Napolitano; Peter J Schwartz; Robert M Joseph; Karen Condouris; Helen Tager-Flusberg; Silvia G Priori; Michael C Sanguinetti; Mark T Keating
Journal:  Cell       Date:  2004-10-01       Impact factor: 41.582

8.  NOS1AP is a genetic modifier of the long-QT syndrome.

Authors:  Lia Crotti; Maria Cristina Monti; Roberto Insolia; Anna Peljto; Althea Goosen; Paul A Brink; David A Greenberg; Peter J Schwartz; Alfred L George
Journal:  Circulation       Date:  2009-10-12       Impact factor: 29.690

9.  Genome-wide mapping of human loci for essential hypertension.

Authors:  Mark Caulfield; Patricia Munroe; Janine Pembroke; Nilesh Samani; Anna Dominiczak; Morris Brown; Nigel Benjamin; John Webster; Peter Ratcliffe; Suzanne O'Shea; Jeanette Papp; Elizabeth Taylor; Richard Dobson; Joanne Knight; Stephen Newhouse; Joel Hooper; Wai Lee; Nick Brain; David Clayton; G Mark Lathrop; Martin Farrall; John Connell
Journal:  Lancet       Date:  2003-06-21       Impact factor: 79.321

10.  Common variants at ten loci modulate the QT interval duration in the QTSCD Study.

Authors:  Arne Pfeufer; Serena Sanna; Dan E Arking; Martina Müller; Vesela Gateva; Christian Fuchsberger; Georg B Ehret; Marco Orrú; Cristian Pattaro; Anna Köttgen; Siegfried Perz; Gianluca Usala; Maja Barbalic; Man Li; Benno Pütz; Angelo Scuteri; Ronald J Prineas; Moritz F Sinner; Christian Gieger; Samer S Najjar; W H Linda Kao; Thomas W Mühleisen; Mariano Dei; Christine Happle; Stefan Möhlenkamp; Laura Crisponi; Raimund Erbel; Karl-Heinz Jöckel; Silvia Naitza; Gerhard Steinbeck; Fabio Marroni; Andrew A Hicks; Edward Lakatta; Bertram Müller-Myhsok; Peter P Pramstaller; H-Erich Wichmann; David Schlessinger; Eric Boerwinkle; Thomas Meitinger; Manuela Uda; Josef Coresh; Stefan Kääb; Gonçalo R Abecasis; Aravinda Chakravarti
Journal:  Nat Genet       Date:  2009-03-22       Impact factor: 38.330

View more
  49 in total

1.  The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes.

Authors:  Elijah R Behr; Craig January; Eric Schulze-Bahr; Andrew A Grace; Stefan Kääb; Monica Fiszman; Shaniece Gathers; Shaavhrée Buckman; Ashraf Youssef; Munir Pirmohamed; Dan Roden
Journal:  Eur Heart J       Date:  2012-07-02       Impact factor: 29.983

2.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

Review 3.  Genetic testing for inherited cardiac disease.

Authors:  Arthur A M Wilde; Elijah R Behr
Journal:  Nat Rev Cardiol       Date:  2013-07-30       Impact factor: 32.419

4.  Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.

Authors:  David G Strauss; Jose Vicente; Lars Johannesen; Ksenia Blinova; Jay W Mason; Peter Weeke; Elijah R Behr; Dan M Roden; Ray Woosley; Gulum Kosova; Michael A Rosenberg; Christopher Newton-Cheh
Journal:  Circulation       Date:  2017-02-17       Impact factor: 29.690

Review 5.  Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Karim Sallam; Yingxin Li; Philip T Sager; Steven R Houser; Joseph C Wu
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

6.  'Social distancing' of the neuronal nitric oxide synthase from its adaptor protein causes arrhythmogenic trigger-substrate interactions in long QT syndrome.

Authors:  Andrew Tieu; Fadi G Akar
Journal:  Cardiovasc Res       Date:  2021-01-21       Impact factor: 10.787

Review 7.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

Review 8.  Drug-induced arrhythmia: pharmacogenomic prescribing?

Authors:  Elijah R Behr; Dan Roden
Journal:  Eur Heart J       Date:  2012-10-22       Impact factor: 29.983

Review 9.  Highlights of the year in JACC 2012.

Authors:  Anthony N DeMaria; Jeroen J Bax; Gregory K Feld; Barry H Greenberg; Jennifer L Hall; Mark A Hlatky; Wilbur Y W Lew; João A C Lima; Ehtisham Mahmud; Alan S Maisel; Sanjiv M Narayan; Steven E Nissen; David J Sahn; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2013-01-22       Impact factor: 24.094

10.  NOS1AP Functionally Associates with YAP To Regulate Hippo Signaling.

Authors:  Leanne Clattenburg; Michael Wigerius; Jiansong Qi; Jan K Rainey; Jillian L Rourke; Shanmugam Muruganandan; Christopher J Sinal; James P Fawcett
Journal:  Mol Cell Biol       Date:  2015-04-27       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.